Abstract
Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Current Cancer Therapy Reviews
Title: Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Volume: 4 Issue: 2
Author(s): Dirk Schadendorf, Jochen Utikal, Balwir Matharoo-Ball, Robert C. Rees and Selma Ugurel
Affiliation:
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Abstract: Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Export Options
About this article
Cite this article as:
Schadendorf Dirk, Utikal Jochen, Matharoo-Ball Balwir, Rees C. Robert and Ugurel Selma, Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310061
DOI https://dx.doi.org/10.2174/157339408784310061 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations
Anti-Cancer Agents in Medicinal Chemistry Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Pharmaceutical Design Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice
Current Pharmaceutical Biotechnology Radiochemotherapy for Non Small Cell Lung Cancer
Current Drug Therapy Radiology of Oropharyngeal Cancer - Institutional Experience and Literature Review -
Current Cancer Therapy Reviews Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry